- Open Access
Factors influencing quality of life of people living with HIV in Estonia: a cross-sectional survey
© Rüütel et al. 2009
- Received: 03 December 2008
- Accepted: 16 July 2009
- Published: 16 July 2009
Identification of factors that determine quality of life is important in order to better tailor health and social care services, and thereby improve the functioning and well being of people living with HIV. The estimated number of people living with HIV in eastern Europe and central Asia is 1.6 million. Little is known about the quality of life of people living with HIV in this region. The main purpose of the present study was to identify the factors influencing quality of life in a sample of HIV-infected persons in Estonia.
A convenient sample of 451 patients attending three infectious diseases clinics for routine HIV clinical care visits was recruited for a cross-sectional survey. The World Health Organization's Quality of Life HIV instrument was used to measure quality of life of the participants and medical data was abstracted from clinical records.
Good overall quality of life was reported by 42.6% (95% CI: 38.0–47.2%) of the study participants (53% men, 60% self-identify as injecting drug users, 82% <30 years of age, 30% with CD4+ T cell count <300 cells/mm3, and 22% on antiretroviral treatment). We identified the following variables as independent predictors of good overall quality of life: being currently employed or studying (AOR: 2.27, 95% CI: 1.18–4.38); and the absence of HIV-related symptoms (AOR: 2.31, 95% CI: 1.24–4.29).
A comprehensive and competent care system, including health care providers and social workers, is required for an effective response. In addition, social interventions should seek to enhance the economic and employment opportunities for people living with HIV in the region.
- Inject Drug User
- Infectious Disease Clinic
- Clinical Care Visit
- Young Inject Drug User
- General Health Facet
A patient's well being is determined not only by his or her health status and response to treatment, but also by other social and psychological dimensions. The identification of factors that determine quality of life (QoL) is important in order to better tailor health and social care services, and thereby improve the functioning and well being of people living with HIV (PLHIV).
In addition, the identification of potentially modifiable factors of QoL could help target people in need of additional services in order to improve QoL . Besides physical and mental health-related factors, socio-demographic characteristics, such as age, gender, education, income and employment status, have been found to be strongly associated with the QoL of PLHIV [2–4].
During the third decade of the AIDS era, new HIV epidemics continue to occur. One of the most recent and rapid increases in the number of new HIV infections in the world has taken place in the newly independent states of the former Soviet Union . The estimated number of PLHIV in eastern Europe and central Asia is 1.6 million (1.2 million–2.1 million) . In eastern Europe, injecting drug users (IDUs) accounted for 62% of all newly diagnosed HIV cases in 2006 . Little is known about the QoL of PLHIV in this region.
The purpose of this study was to examine QoL among Estonian HIV-infected individuals, and to assess the impact of socio-demographic and disease-related variables on QoL in order to facilitate the development of treatment and social care programmes and interventions.
Setting and sample
In 2005, a cross-sectional survey was conducted using a convenient sample of HIV-infected patients attending for routine clinical care visits. We recruited study subjects from infectious diseases clinics in Tallinn, the capital of Estonia (N = 1), and in the north-eastern Ida-Viru county (N = 2). In total, 58% of the Estonian population live in the capital region and in north-eastern Estonia . Importantly, approximately 90% of all HIV cases in Estonia are diagnosed in Tallinn and north-eastern Estonia  and, together, these three infectious diseases clinics serve more than 95% of all HIV-infected patients in care in Estonia .
These clinics provide both in-patient and out-patient infectious disease health care services, including HIV-specific services and antiretroviral (ARV) treatment. In each of the three clinics, one physician was contracted for the recruitment of study subjects, and was asked to enrol a minimum of 150 adult HIV-positive patients from an out-patient clinic.
Inclusion criteria for study subjects were that they be: more than 18 years old; have the ability to read and write in Estonian or Russian; and have been aware of their HIV-infection status for more than three months.
After determining eligibility and securing informed consent, all participants filled in the questionnaire designed for self-administration, which required between 45 and 60 minutes to complete. Participants received supermarket food vouchers to the value of approximately USD 10, equivalent to about 100 kroon (EEK), as an incentive for study participation.
A self-administered survey was used for socio-demographic, HIV-related risk behaviour and QoL assessment. Clinical characteristics were obtained from medical records.
QoL data was collected using the World Health Organization's Quality of Life HIV (WHOQOL-HIV) instrument. The WHOQOL-HIV contains 29 facets, each with four items, which are subsumed in six domains: physical, psychological, level of independence, social, environmental and spiritual. There is also a general facet that measures the overall QoL and general health perceptions (overall QoL). Items are rated on a 5-point Likert interval scale where 1 indicates low, negative perceptions, and 5 indicates high, positive perceptions. Facet scores are the mean of the four items in each facet. Domain scores are obtained by adding the facet means in the respective domain, dividing by the number of facets in that domain, and multiplying by 4, so that scores ranged from 4 (worst possible QoL) to 20 (best possible QoL). Adaptation of the WHOQOL-HIV instrument to the setting and to Estonian and Russian languages has been described elsewhere . In short, Estonian and Russian versions of the WHOQOL-HIV proved to be reliable and valid instruments. Cronbach alpha was above 0.70 for the six domains and the overall QoL and general health facet. Each domain was significantly correlated with the overall QoL and general health facet. Asymptomatic people reported significantly better QoL in physical, psychological and independence domains and related facets compared to those people with symptoms or AIDS [; Rüütel K, unpublished data].
We also collected data on socio-demographic characteristics (age, gender, education, marital status and employment status) and self-identified route of HIV-infection acquisition.
Physicians recruiting the patients collected clinical characteristics from hospital records on the basis of a standardized data abstraction form. Data on the stage of HIV infection (no symptoms, symptoms/early HIV disease, and AIDS), duration since diagnosis of HIV (3–6 months, 7–12 months, 1–2 years, 3–5 years, and more than 5 years), CD4 count, co-morbidities (hepatitis B and C, and tuberculosis) and antiretroviral treatment were obtained.
Data entry was done centrally using Microsoft Access. Statistical analysis was performed with R 2.4.0, a language and environment software for statistical computing and graphics. We used proportions or means with standard deviation (for continuous data) to describe socio-demographic (age, region, gender, education and employment status) and health-related factors (disease stage, routes of infection, CD4 count and time since HIV diagnosis) in different QoL groups.
For the purposes of the factors of QoL analysis, participants were divided into two groups based on the mean score of the facet, "overall quality of life and general health perceptions" (range 1 to 5). Participants with mean scores of >3.0 were categorized as having good QoL, and their counterparts (mean scores of ≤ 3.0) as having poor QoL.
Odds ratios (OR) and 95% confidence intervals (95% CI), together with p-values, were used to identify variables associated with reporting good QoL. A multivariate analysis was performed using logistic regression, taking QoL (good/poor) as the binary dependent variable and the variables related to QoL in the univariate analyses as the covariates to evaluate the independent contribution of variables to QoL.
The magnitude of the association between covariates and QoL in univariate and multivariate analysis was evaluated through odds ratios, together with their corresponding 95% confidence intervals. P-values of less of 0.05 were considered as statistically significant.
Ethical approval was obtained from the Tallinn Medical Research Ethics Committee.
A total of 562 HIV-infected patients were approached for study participation between 1 June and 31 August 2005. Altogether, 451 (80%) were enrolled. The reasons for non-participation were as follows: refusal (50%, 56/111), being aware of HIV-infection status for less than three months (37%, 41/111), and being younger than 18 years at the time of the study (13%, 14/111). In all, 150 patients were recruited in the capital city, Tallinn (33%) and 301 in north-eastern Estonia (67%).
Socio-demographic, HIV disease and co-infection related characteristics of the participants
Place of living
Ida-Viru county, north-eastern Estonia
Capital city, Tallinn
≤9 years of formal education
>9 years of formal education
Working or studying
HIV disease related
HIV transmission category (self-report)
Injecting drug use
Time of HIV diagnosis
1 to 2 years
Stage of HIV-infection
Early HIV disease
Current ARV treatment
Ever had tuberculosis
Ever had hepatitis B or C
Quality of life
Mean scores for overall quality of life and general health perceptions and for six domains
Mean score (SD)
Overall QoL and general health perceptions
Univariate and multivariate factors associated with good quality of life among HIV-infected persons in Estonia
Place of living
Ida-Viru county, north-eastern Estonia
Capital city, Tallinn
Employed and/or studying
HIV disease related
HIV transmission category (self report)
Injecting drug use
Time of HIV diagnosis
≥12 months ago
<12 months ago
Stage of HIV-infection
Early HIV disease/AIDS
Current ARV treatment
Hepatitis B and/or C co-infection
In multivariate analysis (logistic regression model), after including variables significant in univariate analysis into the model, being currently employed or studying (AOR: 2.27, 95% CI: 1.18–4.38), and the absence of HIV-related symptoms (AOR: 2.31, 95% CI: 1.24–4.29) were identified as independent predictors of good QoL (Table 3).
This is the first study describing factors influencing QoL of HIV-infected persons from an eastern European country, a region that has witnessed a relatively recent HIV epidemic driven by injection drug use. It has been suggested that transmission of 80% of HIV infections in former Soviet Union countries is attributable to sharing needles and syringes .
The mean overall QoL score for the whole sample (2.90 ± 0.84) was slightly lower than that reported from similar studies from other regions. O'Connell and colleagues have described a mean overall QoL score (measured by WHOQOL) of 3.2 ± 0.88 for a sample of 590 HIV-infected persons from six culturally diverse sites in Australia, Brazil, India (two sites), Thailand and Zimbabwe .
Further, we can argue that our study overestimated the QoL of PLHIV in Estonia. Several studies have documented better physical health-related QoL among former IDUs than in current IDUs [14, 15]. IDUs often struggle with multiple health risks due to social, economic and psychological factors. Getting HIV care may not be their top concern because they face other more pressing daily challenges, such as addiction, poverty, incarceration, homelessness, depression, mental illness and past trauma .
Given this and the highly stigmatised nature of illegal drug use, both former and current injecting drug users are less likely to receive HIV-related medical care – this is the case in Estonia – and hence they may be under-represented in the clinical samples of PLHIV. In our sample, 60% of participants reported having used injecting drugs.
In our study, the independent and most influential contributors to the general QoL were a person's employment status and clinician-recorded HIV-disease stage. The employed participants, including those who were studying, were more likely to have good general QoL than their not-working counterparts. Our findings are consistent with previous research, which has demonstrated that employment (and higher income) is associated with a better QOL among PLHIV [17, 18].
Controlling for disease severity, employed individuals report significantly higher level of perceived QoL than those who are unemployed [19–21]. Besides financial benefits, employment also provides a source for structure, social support, role identity and meaning. In addition, stable income and employment have been associated with adherence to highly active antiretroviral treatment .
Employment may also provide resources, which buffer the effects of the stress of HIV infection and thus serves to maintain a sense of quality of life . Therefore, return-to-work programmes and other interventions to enhance the economic and employment opportunities are important for PLHIV in eastern Europe and the Russian Federation. Here, young injecting drug users are the main HIV risk group, and unemployment among them is high.
According to our results, asymptomatic patients reported better QoL than those with symptoms or AIDS diagnosis. This factor is amenable for clinical interventions. Quality of life can be altered by both the immediate effects and the longer-term consequences of antiretroviral treatment. Persons with advanced HIV disease and low QoL scores have demonstrated significant improvements in QoL with ARV treatment [23, 24].
Other disease-related factors and co-infection with hepatitis B or C were not associated with better QoL in our sample. Nevertheless, given the extremely high (>90%) hepatitis C infection rates among IDUs in the region and the high proportion of IDUs among PLHIV [25, 26], co-infections with hepatitis B or C warrant attention. Several previous studies have suggested that hepatitis C infection significantly reduces health-related QoL [27, 28], and this effect can be inversed with antiviral treatment . Chronic hepatitis B infection similarly negatively impacts on QoL .
With improvements in HIV treatment, liver disease has become a major cause of hospitalisation and death in PLHIV and complications related to hepatitis B or C co-infection are becoming an increasingly important medical issue. Proper prevention, screening and management of co-infections are of great concern given the high rates of hepatitis B and C infections in Estonia.
Our study had limitations. Given the design of the study, we are able to demonstrate neither causality nor the direction of the described associations. The degree to which the study is representative of the larger HIV-infected population is influenced by the potential selective factors associated with recruiting from HIV treatment settings.
Our results most likely overestimate the QoL of those infected with HIV, as we have discussed. We were successful in recruiting people who are in HIV care in Estonia by sampling from the facilities that provide 95% of HIV care in the country. We also achieved a high participation rate in a specified study period.
To decrease the potential for social desirability bias, we used a self-administered survey instrument for risk behaviour data collection. To enhance the validity of the data on health status, we complemented self-reports with clinical data abstracted from clinical records.
In conclusion, HIV disease status and employment were the important factors influencing QoL of PLHIV in Estonia. A comprehensive and competent care system, including medical staff and social workers, is required for an effective response. In addition, social interventions should seek to enhance the economic and employment opportunities for PLHIV.
This data contributes to the input needed for planning health care services and interventions that address QoL improvement for PLHIV in eastern Europe and central Asia.
This study was funded by: the Global Fund to Fight HIV, Tuberculosis and Malaria's programme, "Scaling up the response to HIV in Estonia"; the Embassy of the United States of America in Estonia's project, "HIV and human rights: reducing the stigma on three levels: prevention, quality of services and policy"; and the grant No. R01 TW006990 from the Fogarty International Center, National Institutes of Health, USA.
The authors are grateful to the participants and the study team for their cooperation.
- McDonnell KA, Gielen AC, O'Campo P, Burke JG: Abuse, HIV status and health-related quality of life among a sample of HIV positive and HIV negative low income women. Quality of Life Research 2005, 14: 945–957.View ArticlePubMedGoogle Scholar
- Cowdery JE, Pesa JA: Assessing quality of life in women living with HIV infection. AIDS Care 2002, 14 (2) : 235–245.View ArticlePubMedGoogle Scholar
- Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C: Quality of life in persons with human immunodeficiency virus infection: Measurement by the medical outcomes study instrument. Ann Intern Med 1992, 116: 129–137.PubMedGoogle Scholar
- Murri R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O, Wu AW: Determinants of health-related quality of life in HIV-infected patients. AIDS Care 2003, 15 (4) : 581–590.View ArticlePubMedGoogle Scholar
- Rüütel K, Uusküla A: HIV epidemic in Estonia in the third decade of AIDS era. Scandinavian Journal of Infectious Diseases 2005, 38: 181–186.Google Scholar
- UNAIDS/WHO: AIDS Epidemic Update. Geneva 2007.Google Scholar
- EuroHIV: HIV/AIDS Surveillance in Europe. Mid-year report. 2007., (76) : Google Scholar
- Database of Statistical Office of Estonia [http://www.stat.ee/rahvastik]
- Database of Estonian Health Protection Inspectorate [http://www.tervisekaitse.ee/?page=102]
- Database of National Institute for Health Development [http://www.tai.ee/?id=4043]
- Rüütel K, Uusküla A, Minossenko A, Loit HM: Quality of life of people living with HIV and AIDS in Estonia. Cent Eur J Public Health. 2008, 16 (3) : 111–115.PubMedGoogle Scholar
- Rüütel K, Loit HM, Uusküla A: Psychometric properties of Russian version of WHOQOL-HIV instrument. The 5th European Conference on Clinical and Social Research on AIDS and Drugs: 28–30 April 2009; Vilnius, Lithuania Abstract no PE3.3/7.Google Scholar
- WHOQOL-HIV Group: Preliminary development of the World Health Organization's Quality of Life HIV Instrument (WHOQOL-HIV): analysis of the pilot version. Social Science and Medicine 2003, 57: 1259–1275.View ArticleGoogle Scholar
- Preau M, Protopopescu C, Spire B, Sobel A, Dellamonica P, Moatti JP, Carrieri MP: Health related quality of life among both current and former injection drug users who are HIV-infected. Drug Alcohol Depend. 2007, 86 (2–3) : 175–182.View ArticlePubMedGoogle Scholar
- Costenbader EC, Zule WA, Coomes CM: The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for hepatitis C infection. Drug Alcohol Depend. 2007, 89 (2–3) : 251–258.View ArticlePubMedGoogle Scholar
- Galea S, Vlahov D: Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep 2002, 117 (Suppl 1) : S135–145.PubMedGoogle Scholar
- Blalock AC, MacDaniel JS, Farber EW: Effect of employment on quality of life and psychological functioning in patients with HIV/AIDS. Psychosomatics 2002, 43: 400–404.View ArticlePubMedGoogle Scholar
- Worthington C, Krentz HB: Socio-economic factors and health-related quality of life in adults living with HIV. International Journal of STD & AIDS 2005, 16 (9) : 608–614.View ArticleGoogle Scholar
- Low-Beer S, Chan K, Wood E, Yip B, Montaner JS, O'Shaughnessy MV, Hogg RS: Health related quality of life among persons with HIV after the use of protease inhibitors. Quality of Life Research 2000, 9: 941–949.View ArticlePubMedGoogle Scholar
- Mrus JM, Leonard AC, Yi MS, Sherman SN, Fultz SL, Justice AC, Tsevat J: Health-related quality of life in veterans and nonveterans with HIV/AIDS. J Gen Intern Med 2006, 21: S39–47.View ArticlePubMedGoogle Scholar
- Sowell RL, Seals BF, Moneyham L, Demi A, Cohen L, Brake S: Quality of life in HIV-infected women in the south-eastern United States. AIDS Care 1997, 9 (5) : 501–512.View ArticlePubMedGoogle Scholar
- Carballo E, Cadarso-Suarez C, Carrera I, Fraga J, de la Fuente J, Ocampo A, Ojea R, Prieto A: Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Quality of Life Research 2004, 13: 587–599.View ArticlePubMedGoogle Scholar
- Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P, the Advanced HIV Disease Ritonavir Study Group: A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS 1998, 12: 1495–1502.View ArticlePubMedGoogle Scholar
- Nieuwkerk PT, Gisolf EH, Reijers MHE, Lange JMA, Danner SA, Sprangers MAG: Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001, 15: 1985–1991.View ArticlePubMedGoogle Scholar
- Tefanova V, Tallo T, Kutsar K, Priimägi L: Current trends in the epidemiology of viral hepatitis B and C in Estonia. EpiNorth 2005, 3 (6) : 57–61.Google Scholar
- Uusküla A, McNutt LA, Dehovitz J, Fischer K, Heimer R: High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia. Int J STD AIDS 2007, 18 (1) : 41–46.View ArticlePubMedGoogle Scholar
- Foster G, Goldin R, Thomas H: Chronic hepatitis C virus infection causes a significant reduction in quality of life. Hepatology 1998, 27: 209–212.View ArticlePubMedGoogle Scholar
- Bonkovsky HL, Wooley JM: The Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999, 29: 264–210.View ArticlePubMedGoogle Scholar
- Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group: Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007, 46 (3) : 420–431.View ArticlePubMedGoogle Scholar
- Herdman MJ, Ossa D, Briggs AS, Tafesse E, Iloeje U, Lozano-Ortega G, Levy AR: Impact on quality of life of health states induced by chronic hepatitis B infection: estimates from uninfected and infected persons in Spain. J Clin Virology 2006, 36 (Suppl 2) : S78.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.